Drug Trial Radar · NCT07734753
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,006
Actual
Start
Jul 15, 2025
Primary completion
May 15, 2026
Study completion Aug 15, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 29, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.
Conditions
- Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions
AlirocumabDrug
The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.
Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)Drug
The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or All-Cause MortalityTime frame: From index up to 5 years follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanofi
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.